FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2677-2686 December 27, 2007 Number 26 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Hoffman, E. P. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Duchenne's muscular dystrophy is associated with severe, progressive muscle weakness and typically leads to death between the ages of 20 and 35 years. By inducing specific exon skipping during messenger RNA (mRNA) splicing, antisense compounds were recently shown to correct the open reading frame of the DMD gene and thus to restore dystrophin expression in vitro and in animal models in vivo. We explored the safety, adverse-event profile, and local dystrophin-restoring effect of a single, intramuscular dose of an antisense oligonucleotide, PRO051, in patients with this disease.

Methods Four patients, who were selected on the basis of their mutational status, muscle condition, and positive exon-skipping response to PRO051 in vitro, received a dose of 0.8 mg of PRO051 injected into the tibialis anterior muscle. A biopsy was performed 28 days later. Safety measures, composition of mRNA, and dystrophin expression were assessed.

Results PRO051 injection was not associated with clinically apparent adverse events. Each patient showed specific skipping of exon 51 and sarcolemmal dystrophin in 64 to 97% of myofibers. The amount of dystrophin in total protein extracts ranged from 3 to 12% of that found in the control specimen and from 17 to 35% of that of the control specimen in the quantitative ratio of dystrophin to laminin 2.

Conclusions Intramuscular injection of antisense oligonucleotide PRO051 induced dystrophin synthesis in four patients with Duchenne's muscular dystrophy who had suitable mutations, suggesting that further studies might be feasible.

Source Information

From the Departments of Human and Clinical Genetics (J.C.D., A.A.J., I.B.G., W.S.F., A.A.-R., M.B.-B., J.T.D., G.-J.B.O.), Pathology (K.K.), and Neurology (J.J.V.), Leiden University Medical Center; and Prosensa B.V. (J.C.D., S.J.K., P.F.E., G.J.P.) — both in Leiden, the Netherlands; the Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam (A.J.K.); the Department of Pediatric Neurology, University of Leuven, Leuven, Belgium (N.M.G.); and Afforce Healthcare, The Hague, the Netherlands (E.H.V.).

Address reprint requests to Dr. van Deutekom at Prosensa B.V., Wassenaarseweg 72, 2333 AL Leiden, the Netherlands, or at j.vandeutekom{at}prosensa.nl.

Full Text of this Article

This article has been cited by other articles:

• Yin, H., Moulton, H. M., Betts, C., Seow, Y., Boutilier, J., Iverson, P. L., Wood, M. J.A. (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18: 4405-4414 [Abstract] [Full Text]  
• Jearawiriyapaisarn, N., Moulton, H. M., Sazani, P., Kole, R., Willis, M. S. (2009). Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 0: cvp335v2-cvp335 [Abstract] [Full Text]  
• Manzur, A Y, Muntoni, F (2009). Diagnosis and new treatments in muscular dystrophies. Postgrad. Med. J. 85: 622-630 [Abstract] [Full Text]  
• Mulders, S. A. M., van den Broek, W. J. A. A., Wheeler, T. M., Croes, H. J. E., van Kuik-Romeijn, P., de Kimpe, S. J., Furling, D., Platenburg, G. J., Gourdon, G., Thornton, C. A., Wieringa, B., Wansink, D. G. (2009). Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Natl. Acad. Sci. USA 106: 13915-13920 [Abstract] [Full Text]  
• Habara, Y, Takeshima, Y, Awano, H, Okizuka, Y, Zhang, Z, Saiki, K, Yagi, M, Matsuo, M (2009). In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G->A mutations in introns of the dystrophin gene. J. Med. Genet. 46: 542-547 [Abstract] [Full Text]  
• Manzur, A Y, Muntoni, F (2009). Diagnosis and new treatments in muscular dystrophies. J. Neurol. Neurosurg. Psychiatry 80: 706-714 [Abstract] [Full Text]  
• van de Vosse, E., Verhard, E. M., de Paus, R. A., Platenburg, G. J., van Deutekom, J. C. T., Aartsma-Rus, A., van Dissel, J. T. (2009). Antisense-mediated exon skipping to correct IL-12R{beta}1 deficiency in T cells. Blood 113: 4548-4555 [Abstract] [Full Text]  
• Baughan, T. D., Dickson, A., Osman, E. Y., Lorson, C. L. (2009). Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet 18: 1600-1611 [Abstract] [Full Text]  
• Moreno, P. M. D., Wenska, M., Lundin, K. E., Wrange, O., Stromberg, R., Smith, C. I. E. (2009). A synthetic snRNA m3G-CAP enhances nuclear delivery of exogenous proteins and nucleic acids. Nucleic Acids Res 37: 1925-1935 [Abstract] [Full Text]  
• Yokota, T., Takeda, S., Lu, Q.-L., Partridge, T. A., Nakamura, A., Hoffman, E. P. (2009). A Renaissance for Antisense Oligonucleotide Drugs in Neurology: Exon Skipping Breaks New Ground. Arch Neurol 66: 32-38 [Abstract] [Full Text]  
• Yin, H., Moulton, H. M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P., Wood, M. J.A. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17: 3909-3918 [Abstract] [Full Text]  
• Ivanova, G. D., Arzumanov, A., Abes, R., Yin, H., Wood, M. J. A., Lebleu, B., Gait, M. J. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36: 6418-6428 [Abstract] [Full Text]  
• Manzur, A Y, Kinali, M, Muntoni, F (2008). Update on the management of Duchenne muscular dystrophy. Arch. Dis. Child. 93: 986-990 [Abstract] [Full Text]  
• Vinge, L. E., Raake, P. W., Koch, W. J. (2008). Gene Therapy in Heart Failure. Circ. Res. 102: 1458-1470 [Abstract] [Full Text]  
• Miller, T. M., Smith, R. A., Kordasiewicz, H., Kaspar, B. K. (2008). Gene-Targeted Therapies for the Central Nervous System. Arch Neurol 65: 447-451 [Full Text]  
• Hoffman, E. P. (2007). Skipping toward Personalized Molecular Medicine. NEJM 357: 2719-2722 [Full Text]